Sanofi/Regeneron's sarilumab hits first PhIII arthritis endpoints
This article was originally published in Scrip
Sarilumab, Sanofi and Regeneron Pharmaceuticals' experimental antibody drug, has met its three primary endpoints in a Phase III trial in rheumatoid arthritis. The product was shown to be effective in patients with active, moderate to severe disease, who had responded inadequately to methotrexate therapy, both improving disease signs and symptoms and inhibiting the progression of joint damage.
You may also be interested in...
Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key themes in 2021. Equitable supply and addressing the mental health challenges associated with lockdowns also loom large.
French phama pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.
Sanofi pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.